Shengxuening (SXN) tablet is extracted from the excrement of the silkworm and has effects on hematopoiesis. The main\ncomponents of SXN are chlorophyll derivatives and sodium iron chlorophyllin (SIC). The present study aims to investigate the\nefficiency and safety of SXN on iron deficiency anemia. This phase IV, multicenter, open-label, randomized clinical trial was\nconducted in 31 hospitals in China from June 2001 to April 2002. Adults and children were randomly divided into low-dose (LSXN),\nmedium-dose (M-SXN), and high-dose (H-SXN) groups, respectively. The course of treatment was 1 month. Peripheral\nhemogram levels and iron status were examined before and after treatment. Adults in all three dose groups demonstrated a\nsignificant increase in hemoglobin (HGB) concentration. Children who received SXN treatment in medium and high doses also\ndemonstrated increasedHGB concentration. Reticulocyte counts increased at the end of treatment in theM-SXNandH-SXN adult\ngroups and in theM-SXNchild group. For both children and adults, SXN in the three dose groups was found to significantly elevate\nred blood cell level,mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration.\nThe total effective rate in the SXN-treated group reached 84.8%. Theincidence of adverse events was 4.07%.Themost common side\neffects were nausea (2.83%), diarrhea (0.74%), and rash (0.25%). SXN was proved to be efficient and safe for adults and children\nwith iron deficiency anemia.
Loading....